Global Mefloquine Market Growth Drivers:
Establishment of Novel Organic Salts Based on
Mefloquine is Driving the Growth of the Global Mefloquine Industry:
The
development of novel pharmaceutical tools to effectively deal with tuberculosis
is the order of the day owing to the accelerated development of resistant
strains of Mycobacterium tuberculosis. As per World Health Organization (WHO),
in 2020, approximately 10 million people fell sick with tuberculosis (TB) globally
including 5.6 million men, 3.3 million women and 1.1 million children. The
traditional treatment for multidrug-resistant tuberculosis (MDR-TB) may take up
to 24 months and only 56% of the cases are successfully treated. Novel
potential formulations of a remodeled medication, the antimalarial agent
mefloquine (MFL), which was integrated with organic anions as chemical
adjuvants have been recorded. Mefloquine may be utilized for malaria
prophylaxis and also in combination with additional antimalarial drugs. Eight mefloquine
organic salts were acquired by ion metathesis reaction between mefloquine
hydrochloride ([MFLH][Cl]) and numerous organic acid sodium salts in high
yields. One of the salts, mefloquine mesylate ([MFLH][MsO]), demonstrated raised
water solubility in comparison with [MFLH][Cl]. The establishment of novel
organic salts based on Mefloquine is therefore driving the growth of the Global
Mefloquine Industry, thereby contributing to the Global Mefloquine Industry
Outlook.
For More Queries About "Mefloquine Market" @ https://www.industryarc.com/support.php?id=511483
Recognition of Mefloquine as a Potential Medication to
Fight COVID-19 (Coronavirus) is Propelling the Growth of the Global Mefloquine
Market:
Long-term malaria prophylaxis with weekly mefloquine
has been investigated, Mefloquine may communicate with additional antimalarial
drugs and antiseizure drugs. In July 2021, researchers in Japan suggested that
the antimalarial agent mefloquine could be remodeled to efficiently treat
SARS-CoV-2. As per the lead scientist in the team, Dr. Koichi Watashi, mefloquine
had the highest anti-SARS-CoV-2 action among the tested compounds. The team examined
the possibility of integrating mefloquine with nelfinavir which restricts the
replication step of SARS-CoV-2. They noticed that the two medications acted in
“synergy”. They estimated that mefloquine could decrease the complete viral
load in affected patients to under seven percent and diminish the
‘time-till-virus-elimination’ by 6.1 days. The recognition of Mefloquine as a potential medication to fight COVID-19 (Coronavirus) is propelling the growth
of the Global Mefloquine Market.
Investment:
In March 2019, Bayer Zydus Pharma planned to persist
to finance novel medications. The
firm is gratified with the performance of its equal joint venture (JV) with
Zydus Cadila, as indicated by the official.
Global Mefloquine Market: Competitive Landscape
Media Contact:
Mr. Venkat Reddy
Sales Manager
Email: [email protected]
Contact Sales: +1-970-236-3677